BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has received approval from Health Canada to start its 'Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease,' it was reported on Wednesday.
This is the first trial in Canada to assess pluripotent stem cell-derived dopaminergic neurons in subjects with Parkinson's disease. The company is enrolling 10 patients in the United States and Canada for the trial, with the Canadian trial site at University Health Network, a research and teaching hospital network located in Toronto, Ontario.
The Ph1 study's primary objective is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant.
Lilly presents Phase 3b Taltz (ixekizumab) plus Zepbound (tirzepatide) data at AAD Annual Meeting
Novartis to acquire Excellergy in USD2bn deal
AstraZeneca's tozorakimab meets primary endpoints in two Phase III COPD trials
Pharming receives positive CHMP opinion for Joenja marketing authorisation
Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate
Hoth Therapeutics deploys OpenClaw AI platform for drug discovery
Insilico Medicine and Tenacia expand AI-driven R&D collaboration
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA